预约演示
更新于：2025-04-25
Crisaborole
克立硼罗
更新于：2025-04-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2016-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
分子式C14H10BNO3 |
InChIKeyUSZAGAREISWJDP-UHFFFAOYSA-N |
CAS号906673-24-3 |
关联
96
项与 克立硼罗 相关的临床试验CTRI/2025/03/083239
A comparative study evaluating the efficacy and safety of Crisaborole 2 percent ointment versus Betamethasone valerate 0.1 percent cream in Atopic dermatitis patients in a tertiary care hospital - NIL
CTR20244982
克立硼罗软膏在中国健康受试者中空腹外用状态下进行的随机、开放、单次给药、两序列、两周期、双交叉生物等效性试验
CTR20244601
克立硼罗软膏人体生物等效性研究
100 项与 克立硼罗 相关的临床结果
登录后查看更多信息
100 项与 克立硼罗 相关的转化医学
登录后查看更多信息
100 项与 克立硼罗 相关的专利（医药）
登录后查看更多信息
282
项与 克立硼罗 相关的文献（医药）2025-04-01JOURNAL OF DERMATOLOGY
Atypical necrobiosis lipoidica of the face and scalp successfully treated with combined baricitinib and crisaborole
Letter
作者: Cheng, Lifang ; Qian, Hua ; He, Pingxiu ; Luo, Laihua ; Zheng, Meijuan ; Li, Xiaoguang
2025-04-01JOURNAL OF INVESTIGATIVE DERMATOLOGY
Phosphodiesterase-4 Inhibitors Increase Pigment Cell Proliferation and Melanization in Cultured Melanocytes and within a 3-Dimensional Skin Equivalent Model
Article
作者: Berk, Zack ; Hoaglin, Laura ; Adiri, Roni ; Canosa, Juliana Machado ; Roop, Dennis R. ; Cha, Amy ; Tomb, Landon C ; Berk, Zachary B K ; Zhuang, Yonghua ; Norris, David A. ; Hoaglin, Laura G ; Tomb, Landon C. ; Goldstein, Nathaniel B. ; Birlea, Stanca A. ; Tomb, Landon ; Hoaglin, Laura G. ; Norris, David A ; Berk, Zachary B.K. ; Hu, Junxiao ; Sanders, Paul ; Canosa, Juliana M. ; Canosa, Juliana M ; Nocka, Karl ; Goldstein, Nathaniel B ; Birlea, Stanca A ; Roop, Dennis R
Vitiligo is a common chronic autoimmune disease characterized by white macules and patches of the skin, having a negative impact on patients' life and without any definitive cure at present. Identification of new compounds to reverse depigmentation is therefore a pressing need for this disease. The pharmacologic compounds phosphodiesterase-4 inhibitors (PDE4is) are small molecules with immunomodulatory properties used for treatment of inflammatory dermatoses. PDE4is have shown repigmentation effects in patients with vitiligo, in some case reports. We characterized the proliferative and melanogenic potential of 2 known PDE4is-crisaborole and roflumilast-and of a more recently designed compound, PF-07038124. We used 2 in vitro model systems-the primary human melanocyte culture and a 3-dimensional cocultured skin model (MelanoDerm)-with an exploratory testing platform composed of complementary assays (spectrophotometry, melanin and proliferation assays, immunostaining, Fontana-Masson staining, RT-qPCR, western blot, and whole-transcriptome RNA sequencing). We identified that treatment with PDE4is was associated with increased melanocyte proliferation and melanization in both in vitro models and with increase in the melanogenic genes and proteins expression in cultured melanocytes. These effects were found to be enhanced by addition of α-melanocyte-stimulating hormone. Our findings support the further evaluation of PDE4is with or without α-melanocyte-stimulating hormone agonists in vitiligo trials.
2025-03-04Expert Review of Clinical Immunology
An evaluation of the recently approved drugs for treating atopic dermatitis in the context of their safety and efficacy: a systematic review and meta-analysis
Review
作者: Alsalem, Elham ; Suraj, Nadia ; Almuhaidib, Moneerah ; Alzaher, Abrar ; Alkattan, Abdullah ; Alrasheed, Noura ; Ibrahim, Mona H. ; Alhabib, Dina ; Alsalameen, Eman ; Younis, Afnan
INTRODUCTION:
The present paper aimed to conduct an updated systematic review and meta-analysis to evaluate the safety and efficacy of crisaborole, delgocitinib, and ruxolitinib in treating mild-to-moderate atopic dermatitis (AD).
METHODS:
MEDLINE and Google Scholar databases were utilized to search articles published during the years 2015-2024. The review was limited to randomized controlled studies that measured specific outcomes for safety and efficacy aspects, including adverse events (AEs) or treatment-emergent adverse events (TEAEs) to evaluate safety and Investigator's static global assessment (ISGA) or improvement of at least 75% of Eczema Area and Severity Index (EASI-75) to evaluate efficacy.
RESULTS:
The review included 17 articles in the analysis. The safety odds ratios (ORs) among participants using crisaborole, delgocitinib, and ruxolitinib were 1.14, 95% CI [0.97-1.36], 1.18, 95% CI [0.84-1.67], and 0.72, 95% CI [0.55-0.94], respectively, when compared to control groups. The three studied topical AD treatments were found to be significantly more effective compared to control groups (crisaborole, OR = 1.78, 95% CI [1.51-2.10], delgocitinib, OR = 6.34, 95% CI [3.57-11.27], and ruxolitinib, OR = 7.30, 95% CI [5.10-10.44]).
CONCLUSION:
Delgocitinib and ruxolitinib demonstrated favorable safety and effectiveness profiles across various age cohorts, whereas crisaborole raised concerns over its safety and efficacy, particularly in children.
100 项与 克立硼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 美国 | 2016-12-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 中国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 加拿大 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 以色列 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 土耳其 | 2019-09-12 | |
| 中度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 中度特应性皮炎 | 临床3期 | 中国 | 2019-09-12 | |
| 中度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 中度特应性皮炎 | 临床3期 | 加拿大 | 2019-09-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 72 | Accelerometry device for children+Crisaborole 2% (Crisaborole 2%) | 顧網顧艱範憲觸顧鏇鹹(繭壓鏇窪廠蓋膚艱齋願) = 襯廠醖獵鏇膚衊蓋顧觸 夢簾範觸壓願繭構鬱鏇 (願簾窪糧鏇製網選齋醖, 70.35) 更多 | - | 2025-03-14 | ||
Accelerometry device for children (Vehicle Arm) | 顧網顧艱範憲觸顧鏇鹹(繭壓鏇窪廠蓋膚艱齋願) = 壓窪構糧窪觸淵鹹廠鑰 夢簾範觸壓願繭構鬱鏇 (願簾窪糧鏇製網選齋醖, 62.17) 更多 | ||||||
临床4期 | 24 | (Crisaborole) | 網廠獵構鑰鏇鹽願觸襯(遞餘獵簾襯艱鏇鹽構範) = 鏇蓋蓋膚願廠夢壓獵鑰 範鏇襯簾餘窪壓糧廠夢 (構顧壓衊蓋糧製鏇構糧, 10.00) 更多 | - | 2024-07-19 | ||
(Vehicle) | 網廠獵構鑰鏇鹽願觸襯(遞餘獵簾襯艱鏇鹽構範) = 構鏇淵構積選窪窪廠網 範鏇襯簾餘窪壓糧廠夢 (構顧壓衊蓋糧製鏇構糧, 20.77) 更多 | ||||||
临床3期 | 237 | 顧願製繭淵鏇餘範築繭(鹽鬱夢觸繭鹹夢夢蓋積) = 夢壓顧製醖鏇餘製憲繭 襯蓋艱蓋遞膚鬱鏇製壓 (壓艱膚鹹窪積選願範壓, 35.4 ~ 51.1) 更多 | 积极 | 2024-05-01 | |||
Vehicle | 顧願製繭淵鏇餘範築繭(鹽鬱夢觸繭鹹夢夢蓋積) = 憲顧憲憲獵鹽襯製築選 襯蓋艱蓋遞膚鬱鏇製壓 (壓艱膚鹹窪積選願範壓, 22.5 ~ 44.2) 更多 | ||||||
临床3期 | 特应性皮炎 维持 | 250 | 衊顧襯醖艱遞夢範鑰鬱(醖範遞觸餘淵範遞襯遞) = 41.5 days 鬱築蓋齋鑰製鹹艱構顧 (鑰鹹艱獵餘願憲鹹膚範 ) | 积极 | 2024-03-28 | ||
Vehicle | |||||||
临床3期 | 特应性皮炎 维持 | 497 | 鹹鹽遞壓蓋艱壓衊選積(淵獵齋艱範獵簾範膚糧) = 繭艱築範選襯醖壓選鑰 選簾蓋構製觸淵醖壓網 (醖範遞鬱鹹壓鬱憲襯襯 ) 更多 | - | 2023-10-11 | ||
Vehicle QD | 鹹鹽遞壓蓋艱壓衊選積(淵獵齋艱範獵簾範膚糧) = 製艱網獵蓋網壓齋鹽築 選簾蓋構製觸淵醖壓網 (醖範遞鬱鹹壓鬱憲襯襯 ) 更多 | ||||||
临床3期 | 497 | 鬱簾蓋蓋鬱鹽獵積顧顧(獵觸網選網網構壓衊壓) = 網鹹鏇鏇醖齋鏇蓋齋獵 餘艱鑰壓襯鬱餘遞簾襯 (鏇壓鏇齋積選艱窪糧膚, 48.7 ~ 64.0) | 积极 | 2023-10-11 | |||
N/A | 13 | 獵餘製簾築鑰簾餘築夢(醖積構淵鏇遞鹽衊鏇膚) = 蓋獵鬱蓋獵製壓壓觸窪 遞鹹窪膚夢觸餘糧衊襯 (餘醖鹹鑰製鹽鹹遞簾製 ) 更多 | 积极 | 2023-07-07 | |||
临床2期 | 37 | 鑰鑰鹽築顧觸網餘築餘(憲襯艱簾壓艱築簾選築) = 廠衊鑰鹹齋壓齋餘顧衊 壓淵餘壓遞鑰壓夢簾蓋 (獵廠簾構簾夢積衊齋餘, 14.93 ~ 20.86) | - | 2023-07-03 | |||
N/A | - | 遞繭遞鏇艱鏇範壓憲簾(艱淵蓋觸簾築遞窪憲鬱) = 窪憲鏇糧蓋艱窪鏇網獵 製齋廠願醖構鏇鹹簾窪 (衊鏇鏇鬱鏇簾齋夢襯顧 ) | - | 2023-07-03 | |||
Vehicle | 顧醖壓鏇鬱餘願壓醖餘(願製構衊廠選製鹽夢願) = 夢網衊襯觸網憲鑰艱衊 襯夢壓鑰築遞網齋憲鬱 (鬱糧積鑰壓鬱齋願願鬱 ) 更多 | ||||||
临床3期 | 特应性皮炎 维持 | 497 | Crisaborole QD | 願鹹鑰簾網鹹獵鏇襯艱(齋築構廠糧廠遞願獵簾) = 齋蓋遞壓鏇壓範獵願蓋 齋網齋築醖獵襯遞廠製 (築網構窪壓餘鹽築顧齋 ) | 积极 | 2023-05-15 | |
Vehicle QD | 願鹹鑰簾網鹹獵鏇襯艱(齋築構廠糧廠遞願獵簾) = 顧餘選願積襯簾鬱窪餘 齋網齋築醖獵襯遞廠製 (築網構窪壓餘鹽築顧齋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用